Potential Nitric Oxide Treatment for Resistant Bacterial Infections Gets Patent

A possible inhalable treatment for antibiotic-resistant bacterial infections in people with cystic fibrosis due to Pseudomonas aeruginosa now has a U.S. patent and is being readied for a first clinical trial, Novoclem Therapeutics announced.

The patent (No. 9,850,322) was issued to the University of North Carolina (UNC) at Chapel Hill where the potential therapy, BIOC51, was discovered, and covers a technology known as water-soluble polyglucosamine compositions that release nitric oxideContinue reading Potential Nitric Oxide Treatment for Resistant Bacterial Infections Gets Patent

Phase 2 Trial of Its Nitric Oxide Product as Cystic Fibrosis Treatment

Novoteris to Start Phase 2 Trial of Its Nitric Oxide Product Thiolanox as Cystic Fibrosis Treatment

https://cysticfibrosisnewstoday.com/2017/06/06/novoteris-to-start-phase-2-trial-of-its-nitric-oxide-therapy-thiolanux-for-cystic-fibrosis/?utm_source=Cystic+Fibrosis&utm_campaign=64d2239573-RSS_MONDAY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b075749015-64d2239573-71418393

by Daniela Semedo, PhD, In Cystic Fibrosis News Today

Continue reading Phase 2 Trial of Its Nitric Oxide Product as Cystic Fibrosis Treatment